Does perioperative systemic therapy represent the optimal therapeutic paradigm in organ-confined, muscle-invasive urothelial carcinoma?
- PMID: 34737893
- PMCID: PMC8558855
- DOI: 10.2144/fsoa-2021-0092
Does perioperative systemic therapy represent the optimal therapeutic paradigm in organ-confined, muscle-invasive urothelial carcinoma?
Keywords: adjuvant therapy; bladder cancer; neoadjuvant therapy.
Conflict of interest statement
Financial & competing interests disclosure C Buonerba (in the last 3 years) has provided consulting to Ipsen. His Institution has received research funding from Sanofi, Astellas and AstraZeneca. C Buonerba serves as an editorial board member of Future Science OA. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.
References
-
- Milojevic B, Dzamic Z, Kajmakovic B, Milenkovic Petronic D, Sipetic Grujicic S. Urothelial carcinoma: recurrence and risk factors. J. BUON. 20(2), 391–398 (2015). - PubMed
-
- Sung H, Ferlay J, Siegel RL et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021). - PubMed
-
- Di Lorenzo G, Federico P, De Placido S, Buonerba C. Increased risk of bladder cancer in critical areas at high pressure of pollution of the Campania region in Italy: a systematic review. Crit. Rev. Oncol. Hematol. 96(3), 534–541 (2015). - PubMed
-
- Bada M, de Concilio B, Crocetto F et al. Laparoscopic radical cystectomy with extracorporeal urinary diversion: an Italian single-center experience with 10-year outcomes. Minerva Urol. Nefrol. 72(5), 641–643 (2020). - PubMed